---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-098224"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-09-09T12:10:15+00:00"
generated_at: "2026-09-09T12:15:05.351203+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics appoints former CDC Director Robert Redfield as Chief Scientific Officer

## Summary
- Robert R. Redfield, M.D., former CDC Director, named Chief Scientific Officer effective Sept 9, 2026.
- Redfield brings 40+ years in immunology, infectious disease; cited >40,000 times in scientific literature.
- He will lead scientific strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa.
- Redfield will work with CEO Bradley Burnam and former FDA Commissioner Stephen Hahn.
- Company is clinical-stage biotech developing non-systemic therapies for inflammatory skin diseases.

## SEC filing metadata
- accession: 0001213900-26-098224
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-09-09T12:10:15+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026098224/0001213900-26-098224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026098224/ea0304806-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-098224
- JSON: https://secwatch.observer/filing/0001213900-26-098224.json
- Plain text: https://secwatch.observer/filing/0001213900-26-098224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.